5 Reasons Amgen's Neulasta Biosimilar Might Not Win Approval

Published: Sep 25, 2017

Jefferies analyst, Michael Yee, reiterated his Buy rating on shares of Amgen noting that 2018-2020 consensus may be too low if the Mylan biosimilar, Neulasta, is not approved next month. He believes this would set shares up for a higher multiple like ABBV.

The analyst does not cite evidence that it will not be approved but offers several reasons why it MIGHT not be:

Back to news